Liver Enzyme Elevation After <sup>177</sup>Lu-PSMA Radioligand Therapy for Metastasized Castration-Resistant Prostate Cancer.
Where this comes from
- Record sourced from PubMed, PMID 33990402.
- Also identified by DOI 10.2967/jnumed.120.258533.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
<sup>177</sup>Lu-PSMA radioligand therapy is a promising new option for patients with metastasized castration-resistant prostate cancer, and the spectrum of adverse events with this treatment has to be evaluated. Here, we describe the case of a patient with M1c disease (metastasis to the mediastinum, lungs, bones, and liver) who presented with elevated liver enzyme levels after receiving <sup>177</sup>Lu-PSMA radioligand therapy for castration-resistant prostate cancer. Pretreatment <sup>68</sup>Ga-PSMA PET/CT showed at least 4 liver lesions with low uptake. Overall, the liver uptake was inhomogeneous. Liver biopsy was performed subsequently.
Medical subject headings
- Prostatic Neoplasms, Castration-Resistant
- Lutetium
- Liver